This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

29 Nov 2011

Exelixis & NCI to Develop Cabozantinib against Multiple Cancers

Exelixis and the NCI will carry out a number of clinical trials to evaluate the safety and efficacy of cabozantinib in several cancers, in comparison with other VEGFR2 inhibitors.

US genomics-based discovery company Exelixis has signed a cooperative research and development agreement (CRADA) with the National Cancer Institute’s (NCI) Cancer Therapy Evaluation Program (CTEP) to support further development of the firm’s lead dual MET and VEGFR2 inhibitor compound cabozantinib in a range of solid tumors.


The agreement covers up to 20 active clinical trials per year over the lifetime of the CRADA. A Phase III study evaluating the drug in medullary thyroid cancer recently yielded positive results, and the firm says it is preparing to file an NDA with FDA for this indication. Exelixis is in addition initiating pivotal Phase III studies of cabozantinib in castration-resistant prostate cancer.


Under terms of the CRADA, Exelixis and the NCI will

Related News